BANB.SW
BANB.SW
CH1176493729
BACHEM N
Loading chart...

Company Profile

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

Related stocks

ALK-B.CO
ALK-B.CO • Denmark
ALK-Abelló B A/S
227.4 DKK
7.55B USD 1Y +5.6%
ASND
ASND • Denmark
Ascendis Pharma A/S
229.23 USD
15.08B USD 1Y +6%
TUB.BR
TUB.BR • Belgium
TUBIZE-FIN
170 EUR
8.48B USD 1Y -27%
CRSP
CRSP • Switzerland
CRISPR Therapeutics AG
53.39 USD
5.16B USD 1Y -34.3%
6160.HK
6160.HK • Switzerland
BEONE MEDICINES
209.6 HKD
39.5B USD 1Y +4.3%
6160.HK
6160.HK • Switzerland
BEONE MEDICINES
209.6 HKD
39.5B USD 1Y +4.3%
ONC
ONC • Switzerland
BeOne Medicines Ltd.
354.47 USD
40.33B USD 1Y -0.3%
ONT.L
ONT.L • United Kingdom
OXFORD NANOPORE TECHNOLOGIES PL
213.4 GBp
2.76B USD 1Y +34.5%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
42.4% p.a.
Max Drawdown (5Y)
-73.5%
Sharpe Ratio (5Y)
-0.34
Beta Factor
0.79
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (42.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -73.5% in the extended horizon.
ende